Loading
The 2005 trial that set the treatment every glioblastoma patient still receives. Nothing has replaced it in twenty years.
EORTC 26981 with NCIC CE.3, the Stupp trial, NCT00006353, reported in 2005, set the treatment every glioblastoma patient still receives: radiotherapy with concurrent and adjuvant temozolomide, which nothing has replaced in twenty years. It randomised 573 patients with newly diagnosed glioblastoma to radiotherapy with or without temozolomide, met its primary overall survival endpoint, and its five-year update in 2009 showed a small but real minority of long-term survivors, while the companion analysis by Hegi showed that MGMT promoter methylation predicts benefit. OnCo links it to temozolomide, the MGMT promoter methylation term, Martin J. van den Bent, Monika E. Hegi, Michael Weller and Roger Stupp, and to the brain as a bottleneck. The Stupp regimen has been the control arm of every glioblastoma trial since, and whether anything can beat it remains the field's central question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
575 enrolled.
Step lines join published landmark estimates; the true curve between them is not shown.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Radiotherapy + temozolomide | 287 | 14.6 months | 0.63 (0.52 to 0.75) | <0.001 | link |
| Radiotherapy alone | 286 | 12.1 months | ||||
| Overall survival at 5 years | Radiotherapy + temozolomide | - | 9.8% | - | - | link |
| Radiotherapy alone | - | 1.9% |
Shares Martin J. van den Bent, Monika E. Hegi, Michael Weller, Roger Stupp.
Shares Michael Weller, Roger Stupp, The brain: barrier and sanctuary, Glioma & glioblastoma.
Shares Astrocytoma, IDH-mutant (grades 2 to 4), EORTC, Temozolomide, Glioma & glioblastoma.
Shares Astrocytoma, IDH-mutant (grades 2 to 4), EORTC, Temozolomide, Glioma & glioblastoma.
Shares Roger Stupp, The brain: barrier and sanctuary, Temozolomide, Glioma & glioblastoma.
Shares MGMT promoter methylation, The brain: barrier and sanctuary, Temozolomide, Glioma & glioblastoma.
Shares Monika E. Hegi, Roger Stupp, EORTC, Glioma & glioblastoma.
Shares MGMT promoter methylation, EORTC, Temozolomide, Glioma & glioblastoma.